Donate
Perth In-Person Education Day 17th June

Perth In-Person Patient Education Day

We are excited to invite you to our upcoming In-Person Patient Education Day in Perth this June.

This education day will include the following topics:

  • Harnessing the Immune System: The Future of Lymphoma Therapy
  • Surveillance and Life After Treatment
  • The Role of Exercise in Survivorship

Guest Speakers

Dr Allison Barraclough
Lymphoma Lead and CAR-T Program Director at Fiona Stanley Hospital, Perth WA. Dr Barraclough has a special interest in immunological treatments for lymphoma and in supporting patients in rural and remote areas living with haematological malignancies.

Helena Furdas

Helena graduated from Curtin University in 2009 and began her career in haematology at Royal Perth Hospital in 2010. Since then she has immersed herself in all aspects of malignant haematology and followed the state stem cell transplant service to Fiona Stanley Hospital in 2015. In 2020. Helena transitioned to Sir Charles Gairdner Hospital to establish the Lymphoma Clinical Nurse Consultant position and has been hooked on lymphoma ever since. After earning her Master’s Degree from Monash University in 2023, Helena has progressed to the role of Lymphoma Nurse Practitioner and is passionate about providing clinical expertise to individuals living with lymphoma.

Claire Munsie

Dr Claire Munsie is a Lecturer in Clinical Exercise Physiology at Curtin University and an Accredited Exercise Physiologist with the WA Youth Cancer Service. She has over 15 years of clinical experience, including the past decade working with young people aged 15 to 25 years during and after cancer treatment. Her clinical work delivers individualised exercise interventions to manage treatment side effects and support recovery within multidisciplinary care.

Her research examines exercise as supportive care in cancer, with focus on adolescents and young adults, sarcoma populations, and implementation in health services. She leads co-designed, clinically embedded studies, including pragmatic trials. She also contributes to research on gender diversity and exercise with the Mental Health and Exercise Research Group (MHEX), addressing evidence gaps to inform inclusive practice.
Dr Munsie is involved in postgraduate teaching and supervision, with focus on translating evidence into clinical care.

Agenda

Arrival 12pm Registrations
Presentation 1 12:15pm – 1:00pm Harnessing the Immune System: The Future of Lymphoma Therapy – Dr Allison Barraclough, Haematologist
Presentation 2 1:00pm – 1:45pm Surveillance and Life After Treatment – Helena Furdas, Lymphoma Nurse Practictioner
Break 1:45pm – 2:15pm Light Refreshments
Presentation 3 2:15pm – 2:45pm The Role of Exercise in Survivorship – Claire Munsie, Senior Exercise Physiologist
Close 2:45pm – 3:00pm Wrap Up and Close

There is limited availability for this event, so secure your spot quickly.
This event has already taken place.
Details
Date: Wednesday 17th of June 2026
Time: 12:00pm AWST - 3:00pm AWST
Location: Harry Perkins Institute of Medical Research (North)
6 Verdun St, Nedlands WA 6009
Register to attend
Download Flyer

Support and information

Support Groups & Social Media

Find Out More

Factsheets & Booklets

Find Out More

Fundraise for us

Get started

Cart
Checkout - $0.00
  • 0
  • 1

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note:
Lymphoma Australia staff are only able to reply to emails sent in English language.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.